TY - JOUR
T1 - Effects of single-dose intravenous phenylbutazone on experimentally induced, reversible lameness in the horse
AU - Foreman, J. H.
AU - Barange, A.
AU - Lawrence, L. M.
AU - Hungerford, L. L.
PY - 2008/2
Y1 - 2008/2
N2 - The objective was to test the hypothesis that phenylbutazone (PBZ) alleviates lameness in an adjustable heart bar shoe model of equine foot pain. Eight Quarter Horse mares underwent 4-weekly treatments randomly: 0.9% saline placebo (SAL: 1 mL/45 kg body weight i.v.) with no lameness; SAL with lameness; PBZ (4.4 mg/kg body weight i.v.) with no lameness; and PBZ with lameness. Blinded heart rate (HR) and lameness score (LS) were assessed every 20 min for 2 h and then hourly through 9 h. At 1 h SAL or PBZ was administered. Jugular venous samples were obtained at hours 0, 1, 2, 4, 6, and 8 and were evaluated for packed cell volume (PCV), cortisol, and drug concentrations. Repeated measures anova and t-tests were used to identify PBZ effects at a significance level of P < 0.05. PBZ-treated LS was lower 2-8 h post-treatment, and HR was lower from 2 through 6 h post-treatment (P < 0.05). Phenylbutazone did not change PCV and had minimal effect on cortisol. Mean plasma PBZ and oxyphenbutazone concentrations 7 h after treatment were 7.2-7.5 and 1.6-1.9 μg/mL, respectively. It was concluded that PBZ was efficacious in alleviating lameness in this model. Cortisol and PCV were not discriminating enough to distinguish between PBZ-treated and SAL-treated trials.
AB - The objective was to test the hypothesis that phenylbutazone (PBZ) alleviates lameness in an adjustable heart bar shoe model of equine foot pain. Eight Quarter Horse mares underwent 4-weekly treatments randomly: 0.9% saline placebo (SAL: 1 mL/45 kg body weight i.v.) with no lameness; SAL with lameness; PBZ (4.4 mg/kg body weight i.v.) with no lameness; and PBZ with lameness. Blinded heart rate (HR) and lameness score (LS) were assessed every 20 min for 2 h and then hourly through 9 h. At 1 h SAL or PBZ was administered. Jugular venous samples were obtained at hours 0, 1, 2, 4, 6, and 8 and were evaluated for packed cell volume (PCV), cortisol, and drug concentrations. Repeated measures anova and t-tests were used to identify PBZ effects at a significance level of P < 0.05. PBZ-treated LS was lower 2-8 h post-treatment, and HR was lower from 2 through 6 h post-treatment (P < 0.05). Phenylbutazone did not change PCV and had minimal effect on cortisol. Mean plasma PBZ and oxyphenbutazone concentrations 7 h after treatment were 7.2-7.5 and 1.6-1.9 μg/mL, respectively. It was concluded that PBZ was efficacious in alleviating lameness in this model. Cortisol and PCV were not discriminating enough to distinguish between PBZ-treated and SAL-treated trials.
UR - http://www.scopus.com/inward/record.url?scp=37549007629&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37549007629&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2885.2007.00925.x
DO - 10.1111/j.1365-2885.2007.00925.x
M3 - Article
C2 - 18177317
AN - SCOPUS:37549007629
SN - 0140-7783
VL - 31
SP - 39
EP - 44
JO - Journal of Veterinary Pharmacology and Therapeutics
JF - Journal of Veterinary Pharmacology and Therapeutics
IS - 1
ER -